Literature DB >> 8194874

Deletion mapping of chromosome 19 in human gliomas.

A von Deimling1, J Nagel, B Bender, D Lenartz, J Schramm, D N Louis, O D Wiestler.   

Abstract

There is evidence that a putative glioma tumor suppressor locus resides on the long arm of chromosome 19. We present data on 161 gliomas from 156 patients, which were studied by microsatellite analysis for loss of heterozygosity (LOH) on chromosome 19. Eight loci on the long arm and 2 loci on the short arm of chromosome 19 were examined. LOH on 19q was observed in 3/19 astrocytomas (WHO grade II), 12/27 anaplastic astrocytomas (WHO grade III), 16/76 cases of glioblastoma multiforme WHO (grade IV), 4/9 oligodendrogliomas (WHO grade II), 3/5 anaplastic oligodendrogliomas (WHO grade III), 5/9 mixed oligo-astrocytomas (WHO grade II) and 8/10 anaplastic oligo-astrocytomas (WHO grade III). While 31 of the tumors with LOH on chromosomal arm 19q exhibited allelic loss at every informative locus, 20 tumors showed terminal or interstitial deletions. In contrast to astrocytomas and glioblastomas, tumors with an oligodendroglial component had predominantly lost the entire long arm of chromosome 19. The common region of overlap in gliomas was located on 19q13.2-q13.4 between the markers D19S178 and D19S180. Our data confirm the involvement of a putative tumor suppressor gene on chromosomal arm 19q in gliomas and assign this gene to 19q13.2-q13.4.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8194874     DOI: 10.1002/ijc.2910570511

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  13 in total

1.  Enhancing diagnosis, prognosis, and therapeutic outcome prediction of gliomas using genomics.

Authors:  Mahfoud Assem; Zita Sibenaller; Supreet Agarwal; Maha S Al-Keilani; Mohammad A Y Alqudah; Timothy C Ryken
Journal:  OMICS       Date:  2012-03

2.  Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay.

Authors:  J M Nigro; M A Takahashi; D G Ginzinger; M Law; S Passe; R B Jenkins; K Aldape
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

3.  Acquisition of the glioblastoma phenotype during astrocytoma progression is associated with loss of heterozygosity on 10q25-qter.

Authors:  H Fujisawa; M Kurrer; R M Reis; Y Yonekawa; P Kleihues; H Ohgaki
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

4.  Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization.

Authors:  S H Bigner; M R Matthews; B K Rasheed; R N Wiltshire; H S Friedman; A H Friedman; T T Stenzel; D M Dawes; R E McLendon; D D Bigner
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

Review 5.  Molecular pathogenesis of oligodendroglial tumors.

Authors:  Judith W M Jeuken; Andreas von Deimling; Pieter Wesseling
Journal:  J Neurooncol       Date:  2004-11       Impact factor: 4.130

Review 6.  Pathology and molecular genetics of oligodendroglial tumors.

Authors:  Christian Hartmann; Wolf Mueller; Andreas von Deimling
Journal:  J Mol Med (Berl)       Date:  2004-10       Impact factor: 4.599

7.  Interpreting aCGH-defined karyotypic changes in gliomas using copy number status, loss of heterozygosity and allelic ratios.

Authors:  John K Cowell; Ken C Lo; Jesse Luce; Lesleyann Hawthorn
Journal:  Exp Mol Pathol       Date:  2009-10-07       Impact factor: 3.362

8.  Cerebral glioblastoma with oligodendrogliomal component: analysis of 36 cases.

Authors:  Maurizio Salvati; Anna I Formichella; Alessandro D'Elia; Cristian Brogna; Alessandro Frati; Felice Giangaspero; Roberto Delfini; Antonio Santoro
Journal:  J Neurooncol       Date:  2009-04-03       Impact factor: 4.130

9.  hHSS1: a novel secreted factor and suppressor of glioma growth located at chromosome 19q13.33.

Authors:  Katiana S Junes-Gill; Timothy K Gallaher; Zoya Gluzman-Poltorak; Joseph D Miller; Christopher J Wheeler; Xuemo Fan; Lena A Basile
Journal:  J Neurooncol       Date:  2010-07-31       Impact factor: 4.130

10.  SIRT2 as a Therapeutic Target for Age-Related Disorders.

Authors:  Rita Machado de Oliveira; Jana Sarkander; Aleksey G Kazantsev; Tiago Fleming Outeiro
Journal:  Front Pharmacol       Date:  2012-05-03       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.